Bright.md’s asynchronous virtual care platform, SmartExam, is now available in the Epic App Orchard, allowing for a streamlined implementation process and tight integrations for healthcare systems using Epic EHR tools.
SmartExam is an asynchronous telehealth platform that helps patients navigate to their trusted healthcare provider’s virtual front door, triages patients to the right venue of care based on the complexity of their condition, and lets clinicians deliver treatment for hundreds of low-acuity conditions. SmartExam takes the information gathered from a patient during a self-guided online medical interview and automatically delivers it in a mobile-friendly chart note for easy review by a provider in two minutes or less. This efficiency boosts clinical capacity by as much as 15x.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“Enabling the SmartExam API through App Orchard allows providers to easily access and reference Continuity of Care Document (CCD) data from the patient’s medical record directly within SmartExam,” said Bright.md Vice President of Engineering Robert DiFalco.
Interoperability and the ease of CCD data exchange between SmartExam and patient EHRs has taken on heightened importance in light of the COVID-19 crisis. Systems face resource challenges while patients seek care via telehealth services that may not be tied to their primary care provider. Equipping healthcare providers with a solution that allows them to efficiently provide care and protects the patient’s continuum of care is key.
Cullinan Oncology has closed a $98.5 million Series B funding round. The business, will use the funding to support clinical trials for its small molecule and biologics portfolio. The company’s lead product, in phase 1 trials, is aimed at cancers tied to EBV infection, such as nasopharyngeal cancer and fast-growing lymphomas such as Burkitt lymphoma. The round added institutional investors and family offices to its investors as well as established investors MPM Capital and F2 Ventures. Click here to read more.
Crowdfunding venture investment platform OurCrowd has raised a $100 million fund aimed at supporting technologies around the coronavirus public health crisis. The Pandemic Innovation Fund will invest in the following areas: vaccines, testing, personal protection, therapeutics, diagnostics, cybersecurity remote monitoring, and other digital health areas. The fund will also invest in startups and those already in its portfolio. Click here to read more.
Bigfoot Biomedical closed a $55 million Series C round. Led by medtech company Abbott, the financing will be used to help the business advance its plans to submit an application to the FDA this month for a tool to help people with diabetes calculate the correct dose of insulin. Click here to read more.
Picture: akindo, Getty Images
